We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Institute for Health and Care Excellence is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis (RRMS) after price cuts enabled the cost regulator to endorse their routine use on the NHS.